Charles Schwab Investment Management Inc. Buys 92,338 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Charles Schwab Investment Management Inc. boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,277,266 shares of the medical research company's stock after buying an additional 92,338 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.59% of Thermo Fisher Scientific worth $1,208,750,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Raleigh Capital Management Inc. lifted its position in shares of Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company's stock worth $41,000 after purchasing an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company's stock worth $47,000 after acquiring an additional 46 shares in the last quarter. Financial Connections Group Inc. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $53,000. Operose Advisors LLC lifted its stake in Thermo Fisher Scientific by 250.0% in the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company's stock worth $53,000 after acquiring an additional 75 shares during the last quarter. Finally, Valley National Advisers Inc. boosted its position in shares of Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company's stock worth $56,000 after acquiring an additional 32 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.1 %

Shares of Thermo Fisher Scientific stock traded up $0.77 on Wednesday, hitting $573.64. 1,585,506 shares of the company's stock traded hands, compared to its average volume of 1,549,346. The firm's 50-day moving average price is $575.72 and its two-hundred day moving average price is $535.12. The stock has a market capitalization of $218.97 billion, a PE ratio of 36.80, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific's payout ratio is presently 10.01%.

Wall Street Analyst Weigh In

TMO has been the topic of several research reports. JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a report on Thursday, April 25th. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an "outperform" rating in a report on Thursday, April 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a "buy" rating in a research note on Thursday, April 25th. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating for the company in a report on Thursday, April 25th. Finally, The Goldman Sachs Group raised their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a report on Wednesday, April 10th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $607.35.

Insiders Place Their Bets

In other news, Director Debora L. Spar sold 164 shares of the company's stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Debora L. Spar sold 164 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares of the company's stock, valued at approximately $660,192.79. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $564.72, for a total transaction of $5,647,200.00. Following the transaction, the chief executive officer now owns 128,485 shares in the company, valued at $72,558,049.20. The disclosure for this sale can be found here. Insiders sold 37,711 shares of company stock worth $21,630,972 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.